Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A narrative review of vascular conduits for coronary artery bypass grafting

  • Iraola-Picornell, Georgina
  • Berastegui García, Elisabet|||0000-0002-1766-2970
  • Castells-Sala, Cristina|||0000-0002-7520-5401
  • Martorell, Jordi|||0000-0002-2043-2762
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Calle Arias, Alexandra|||0000-0003-3903-5019
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Cserkóová, Adriana
  • Morancho, Anna|||0000-0001-9059-3206
  • Ramírez de Paz, Miguel Ángel|||0000-0002-5868-2134
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Wharton's jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit, an experienced view

  • Muñoz-Domínguez, Noelia
  • Roura, Santiago|||0000-0003-4063-9661
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particu-larly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Urine NMR-based TB metabolic fingerprinting for the diagnosis of TB in children

  • Comella-del-Barrio, Patricia|||0000-0002-2433-9864
  • Izquierdo-Garcia, José Luis
  • Gautier, Jacqueline
  • Doresca, Mariette Jean Coute
  • Campos-Olivas, Ramón|||0000-0002-5743-2221
  • Santiveri, Clara M.
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Abellana, Rosa|||0000-0003-4487-4431
  • Pérez-Porcuna, Tomás M.|||0000-0002-9951-7768
  • Cuevas, Luis E.|||0000-0002-6581-0587
  • Ruiz-Cabello, Jesús|||0000-0001-8681-5056
  • Domínguez, José|||0000-0001-7888-0309
Tuberculosis (TB) is a major cause of morbidity and mortality in children, and early diagnosis and treatment are crucial to reduce long-term morbidity and mortality. In this study, we explore whether urine nuclear magnetic resonance (NMR)-based metabolomics could be used to identify differences in the metabolic response of children with different diagnostic certainty of TB. We included 62 children with signs and symptoms of TB and 55 apparently healthy children. Six of the children with presumptive TB had bacteriologically confirmed TB, 52 children with unconfirmed TB, and 4 children with unlikely TB. Urine metabolic fingerprints were identified using high- and low-field proton NMR platforms and assessed with pattern recognition techniques such as principal components analysis and partial least squares discriminant analysis. We observed differences in the metabolic fingerprint of children with bacteriologically confirmed and unconfirmed TB compared to children with unlikely TB (p = 0.041 and p = 0.013, respectively). Moreover, children with unconfirmed TB with X-rays compatible with TB showed differences in the metabolic fingerprint compared to children with non-pathological X-rays (p = 0.009). Differences in the metabolic fingerprint in children with different diagnostic certainty of TB could contribute to a more accurate characterisation of TB in the paediatric population. The use of metabolomics could be useful to improve the prediction of TB progression and diagnosis in children.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

N-Glycans in Immortalized Mesenchymal Stromal Cell-Derived Extracellular Vesicles Are Critical for EV-Cell Interaction and Functional Activation of Endothelial Cells

  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Williams, Charles
  • Reichardt, Niels-Christian
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EV) are widely considered as a cell-free therapeutic alternative to MSC cell administration, due to their immunomodulatory and regenerative properties. However, the interaction mechanisms between EV and target cells are not fully understood. The surface glycans could be key players in EV-cell communication, being specific molecular recognition patterns that are still little explored. In this study, we focused on the role of N-glycosylation of MSC-EV as mediators of MSC-EV and endothelial cells' interaction for subsequent EV uptake and the induction of cell migration and angiogenesis. For that, EV from immortalized Wharton's Jelly MSC (iWJ-MSC-EV) were isolated by size exclusion chromatography (SEC) and treated with the glycosidase PNGase-F in order to remove wild-type N-glycans. Then, CFSE-labelled iWJ-MSC-EV were tested in the context of in vitro capture, agarose-spot migration and matrigel-based tube formation assays, using HUVEC. As a result, we found that the N-glycosylation in iWJ-MSC-EV is critical for interaction with HUVEC cells. iWJ-MSC-EV were captured by HUVEC, stimulating their tube-like formation ability and promoting their recruitment. Conversely, the removal of N-glycans through PNGase-F treatment reduced all of these functional activities induced by native iWJ-MSC-EV. Finally, comparative lectin arrays of iWJ-MSC-EV and PNGase-F-treated iWJ-MSC-EV found marked differences in the surface glycosylation pattern, particularly in N-acetylglucosamine, mannose, and fucose-binding lectins. Taken together, our results highlight the importance of N-glycans in MSC-EV to permit EV-cell interactions and associated functions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Teis, Albert|||0000-0002-4820-0736
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Courageux, Yvan|||0000-0002-1484-2677
  • Munizaga-Larroudé, Micaela
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Rationale: Extracellular vesicles (EVs) from mesenchymal stromal cell (MSC) are a potential therapy for cardiac healing after myocardial infarction (MI). Nevertheless, neither their efficient administration nor therapeutic mechanisms are fully elucidated. Here, we evaluate the preclinical efficacy of a tissue engineering approach to locally deliver porcine cardiac adipose tissue MSC-EV (cATMSC-EV) in an acute MI pig model. Methods: After MI by permanent ligation of the coronary artery, pigs (n = 24) were randomized to Untreated or treated groups with a decellularised pericardial scaffold filled with peptide hydrogel and cATMSC-EV purified by size exclusion chromatography (EV-Treated group) or buffer (Control group), placed over the post-infarcted myocardium. Results: After 30 days, cardiac MRI showed an improved cardiac function in EV-Treated animals, with significantly higher right ventricle ejection fraction (+20.8% in EV-Treated; p = 0.026), and less ventricle dilatation, indicating less myocardial remodelling. Scar size was reduced, with less fibrosis in the distal myocardium (-42.6% Col I in EV-Treated vs Untreated; p = 0.03), a 2-fold increase in vascular density (EV-Treated; p = 0.019) and less CCL2 transcription in the infarct core. EV-treated animals had less macrophage infiltration in the infarct core (-31.7% of CD163 + cells/field in EV-Treated; p = 0.026), but 5.8 times more expressing anti-inflammatory CD73 (p = 0.015). Systemically, locally delivered cATMSC-EV also triggered a systemic effect, doubling the circulating IL-1ra (p = 0.01), and reducing the PBMC rush 2d post-MI, the TNFα and GM-CSF levels at 30d post-MI, and modulating the CD73 + and CCR2 + monocyte populations, related to immunomodulation and fibrosis modulation. Conclusions: These results highlight the potential of cATMSC-EV in modulating hallmarks of ischemic injury for cardiac repair after MI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical translation of mesenchymal stromal cell extracellular vesicles, Considerations on scientific rationale and production requisites

  • Courageux, Yvan|||0000-0002-1484-2677
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
The present paper is a commentary to 'Identification and characterization of hADSC - derived exosome proteins from different isolation methods ' (Huang et al. 2021; ). Given the enthusiasm for the potential of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs), some considerations deserve attention as they move through successive stages of research and application into humans. We herein remark the prerequisite of generating that evidence ensuring a high consistency in safety, composition and biological activity of the intended MSC-EV preparations, and the suitability of disparate isolation techniques to produce efficacious EV preparations and fulfil requirements for standardized clinical-grade biomanufacturing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction

  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Rudilla, F
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ferrer-Curriu, Gemma|||0000-0002-2651-649X
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Mellado-Bergillos, Araceli
  • Gomez-Puchades, Pol
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Specific proteins and processes have been identified in post-myocardial infarction (MI) pathological remodeling, but a comprehensive understanding of the complete molecular evolution is lacking. We generated microarray data from swine heart biopsies at baseline and 6, 30, and 45 days after infarction to feed machine-learning algorithms. We cross-validated the results using available clinical and experimental information. MI progression was accompanied by the regulation of adipogenesis, fatty acid metabolism, and epithelial-mesenchymal transition. The infarct core region was enriched in processes related to muscle contraction and membrane depolarization. Angiogenesis was among the first morphogenic responses detected as being sustained over time, but other processes suggesting post-ischemic recapitulation of embryogenic processes were also observed. Finally, protein-triggering analysis established the key genes mediating each process at each time point, as well as the complete adverse remodeling response. We modeled the behaviors of these genes, generating a description of the integrative mechanism of action for MI progression. This mechanistic analysis overlapped at different time points; the common pathways between the source proteins and cardiac remodeling involved IGF1R, RAF1, KPCA, JUN, and PTN11 as modulators. Thus, our data delineate a structured and comprehensive picture of the molecular remodeling process, identify new potential biomarkers or therapeutic targets, and establish therapeutic windows during disease progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation

  • Oliveras, Teresa
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Cserkóová, Adriana
  • Rueda, Ferran|||0000-0001-5464-4870
  • Labata, Carlos|||0000-0002-4505-0787
  • Ferrer Vinardel, Marc|||0000-0002-1283-8578
  • Montero, Santiago|||0000-0002-0984-3472
  • El Ouaddi, Nabil|||0000-0002-5980-8915
  • Martínez, Maria José
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Primary ventricular fibrillation (PVF) is a life-threatening complication of ST-segment elevation myocardial infarction (STEMI). It is unclear what roles viral infection and/or systemic inflammation may play as underlying triggers of PVF, as a second hit in the context of acute ischaemia. Here we aimed to evaluate whether the circulating virome and inflammatory proteome were associated with PVF development in patients with STEMI. Blood samples were obtained from non-PVF and PVF STEMI patients at the time of primary PCI, and from non-STEMI healthy controls. The virome profile was analysed using VirCapSeq-VERT (Virome Capture Sequencing Platform for Vertebrate Viruses), a sequencing platform targeting viral taxa of 342,438 representative sequences, spanning all virus sequence records. The inflammatory proteome was explored with the Olink inflammation panel, using the Proximity Extension Assay technology. After analysing all viral taxa known to infect vertebrates, including humans, we found that non-PVF and PVF patients only significantly differed in the frequencies of viruses in the Gamma-herpesvirinae and Anelloviridae families. In particular, most showed a significantly higher relative frequency in non-PVF STEMI controls. Analysis of systemic inflammation revealed no significant differences between the inflammatory profiles of non-PVF and PVF STEMI patients. Inflammatory proteins associated with cell adhesion, chemotaxis, cellular response to cytokine stimulus, and cell activation proteins involved in immune response (IL6, IL8 CXCL-11, CCL-11, MCP3, MCP4, and ENRAGE) were significantly higher in STEMI patients than non-STEMI controls. CDCP1 and IL18-R1 were significantly higher in PVF patients compared to healthy subjects, but not compared to non-PVF patients. The circulating virome and systemic inflammation were not associated with increased risk of PVF development in acute STEMI. Accordingly, novel strategies are needed to elucidate putative triggers of PVF in the setting of acute ischaemia, in order to reduce STEMI-driven sudden death burden.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).